• MoonLake Immunotherapeutics signed a master commercial supply agreement with Vetter on May 22, 2026, covering manufacture of pre-filled application systems.
• The deal uses product-specific schedules for services and pricing, with Vetter able to adjust pricing for documented cost increases.
• A separate capacity agreement requires binding demand forecasts, with Vetter reserving annual filling capacity up to a maximum quantity.
• MoonLake may owe capacity compensation if orders fall below minimum commitments or if purchase orders are not provided for the binding period.
• The master supply agreement allows termination for uncured material breach, bankruptcy, or certain change-of-control events; no-cause termination requires 12 months’ notice.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moonlake Immunotherapeutics published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-063125), on June 01, 2026, and is solely responsible for the information contained therein.